Share Name Share Symbol Market Type Share ISIN Share Description
Hutchison China Meditech LSE:HCM London Ordinary Share KYG4672N1016 ORD USD1
  Price Change % Change Share Price Shares Traded Last Trade
  +30.00p +0.62% 4,850.00p 7,096 16:35:26
Bid Price Offer Price High Price Low Price Open Price
4,850.00p 4,880.00p 4,865.00p 4,820.00p 4,820.00p
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 178.58 -39.64 -31.84 3,226.8

Hutchison China Meditech (HCM) Latest News

More Hutchison China Meditech News
Hutchison China Meditech Takeover Rumours

Hutchison China Meditech (HCM) Share Charts

1 Year Hutchison China Meditech Chart

1 Year Hutchison China Meditech Chart

1 Month Hutchison China Meditech Chart

1 Month Hutchison China Meditech Chart

Intraday Hutchison China Meditech Chart

Intraday Hutchison China Meditech Chart

Hutchison China Meditech (HCM) Discussions and Chat

Hutchison China Meditech Forums and Chat

Date Time Title Posts
12/11/201815:46(Chi-Med)Hutchinson China Meditech Limited1,680
31/7/201806:25Hutchison Chi-Med (HCM) One to Watch 1
23/7/201809:55Hutchison Chi-Med (HCM) One to Watch on Monday 1
13/6/201706:54Hutchison China Meditech- CHARTS AND DISCUSSION74

Add a New Thread

Hutchison China Meditech (HCM) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all Hutchison China Meditech trades in real-time

Hutchison China Meditech (HCM) Top Chat Posts

Hutchison China Meditech Daily Update: Hutchison China Meditech is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker HCM. The last closing price for Hutchison China Meditech was 4,820p.
Hutchison China Meditech has a 4 week average price of 4,400p and a 12 week average price of 4,225p.
The 1 year high share price is 5,920p while the 1 year low share price is currently 3,985p.
There are currently 66,532,683 shares in issue and the average daily traded volume is 14,242 shares. The market capitalisation of Hutchison China Meditech is £3,226,835,125.50.
nerdofsteel: Volume always seems to increase significantly prior to significant pipeline news.....apart from Fruquintinib approval where absolutely nothing happened with regard to the share price!
sportii: Chi-med share price has not been moving in the positive direction, even after the major news of first drug approval. Due to the unfortunate geopolitical situation, institutional buyers in the USA are not showing any interest. Hence, share price is suffering and we, long time holders, are disappointed. Unless, there are new buyers who are willing to buy, share price will not move up. That will be the case even if the company gets approval for two or more drug candidates. Wondering why the management isn’t interested in listing on HK stock exchange.
sportii: Any early falls in the share price going to bevtransient. Expecting ‘corrections’ by this afternoon.
reptile3: kazoom.... I should have said with reference to the drop on Nasdaq where at 8.30p.m. UK time the share price was 9.3% down on the day and therefore anticipating the drop to around £41 on AIM.
sportii: Everything else, other than the share price, appears positive. Big drop in share price on the other side of the pond, today. Is yesterdsy’s approval news not good enough for the big buyers? Disheartened sellers, perhaps.
lauders: The sudden weakness is probably a combination of two things: 1) The vaccine issue that is rocking China: 2) The likelihood of no news for a few months post the results release. May be time to top-up if the fall becomes overdone. Seems that the US dictates the share price direction these days.
nimrod22: should be seen as a buying opportunity while the share price is slopping around at low volume.
nimrod22: I did wonder if the share price may have suffered because it has "China" in the company name and the frequent news about tariffs?? For anybody following Chinese based shares.. Xiaomi on the Hong Kong board is worth a punt, IPO last Monday at low end of valuation of 17HK$, dropped and since recovered to 21.45HK$. Will also be listed on the Hang Seng index on 23rd July. Plenty of info out there.
dbadvn: Had a very interesting meeting with the CFO . They are certainly sticking to plan and gearing up for European/US sales independently of whatever happens with Lilley etc. Making all the right noises on Clinical/ Sales teams/ Branding/ Competition and realistic on timescale. Not defending the fact that the recent cash raise was basically opportunistic use of perfect market conditions . Looking to be cash flow positive within 5 years ( doe not exclude more cash raising depending on opportunities). The positive "elephant in the room" is the $50bn potential of HMPL 523 in the immunology market. Although still at the early stages HCM seem to have the lead here and only Gilead as competition. Short term lack of news flow may see the share price drift but medium and long term potential probabilities of success are increasing . At some point the US market will start to valur HCM in the same way as the US Biotechs ( less the takeover premium perhaps ) .At that point the share price will react strongly . When that happens is anyones guess so I for one am staying invested long term
nerdofsteel: mad - agree 100%, and if you look back at the share price in London over the last 10 years you see sometimes quite lengthy periods where the share price is stagnant, followed by sharp increases, then further stagnation
Hutchison China Meditech share price data is direct from the London Stock Exchange
add chat code
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:40 V: D:20181112 19:51:35